Integrated Diagnostics Holdings plc
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more
Integrated Diagnostics Holdings plc (IDGXF) - Net Assets
Latest net assets as of June 2025: $3.83 Billion USD
Based on the latest financial reports, Integrated Diagnostics Holdings plc (IDGXF) has net assets worth $3.83 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.50 Billion) and total liabilities ($3.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.83 Billion |
| % of Total Assets | 51.07% |
| Annual Growth Rate | 4.48% |
| 5-Year Change | 44.23% |
| 10-Year Change | 80.16% |
| Growth Volatility | 10.81 |
Integrated Diagnostics Holdings plc - Net Assets Trend (2012–2024)
This chart illustrates how Integrated Diagnostics Holdings plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Integrated Diagnostics Holdings plc (2012–2024)
The table below shows the annual net assets of Integrated Diagnostics Holdings plc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.50 Billion | +12.86% |
| 2023-12-31 | $3.10 Billion | +26.72% |
| 2022-12-31 | $2.45 Billion | -12.43% |
| 2021-12-31 | $2.79 Billion | +15.17% |
| 2020-12-31 | $2.43 Billion | +2.80% |
| 2019-12-31 | $2.36 Billion | -1.68% |
| 2018-12-31 | $2.40 Billion | +3.74% |
| 2017-12-31 | $2.31 Billion | +0.64% |
| 2016-12-31 | $2.30 Billion | +18.38% |
| 2015-12-31 | $1.94 Billion | +4.68% |
| 2014-12-31 | $1.86 Billion | -4.66% |
| 2013-12-31 | $1.95 Billion | -5.95% |
| 2012-12-31 | $2.07 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Integrated Diagnostics Holdings plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 186464909600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.81 Billion | 66.89% |
| Common Stock | $1.04 Billion | 38.34% |
| Total Equity | $2.71 Billion | 100.00% |
Integrated Diagnostics Holdings plc Competitors by Market Cap
The table below lists competitors of Integrated Diagnostics Holdings plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BATM Advanced Communications Ltd.
PINK:BVCLF
|
$74.42 Million |
|
Lucero Energy Corp
V:LOU
|
$74.45 Million |
|
Fission 3.0 Corp
V:FUU
|
$74.46 Million |
|
Korea Information Certificate Authority Inc
KQ:053300
|
$74.46 Million |
|
Brockhaus Technologies AG
LSE:0AAW
|
$74.40 Million |
|
Sasken Technologies Limited
NSE:SASKEN
|
$74.39 Million |
|
Questerre Energy Corporation
PINK:QTEYF
|
$74.39 Million |
|
Veranda Learning Solutions Limited
NSE:VERANDA
|
$74.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Integrated Diagnostics Holdings plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,678,900,000 to 2,710,149,000, a change of 31,249,000 (1.2%).
- Net income of 1,077,434,000 contributed positively to equity growth.
- Dividend payments of 27,421,000 reduced retained earnings.
- Share repurchases of 374,354,000 reduced equity.
- Other comprehensive income increased equity by 753,234,000.
- Other factors decreased equity by 1,397,644,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.08 Billion | +39.76% |
| Dividends Paid | $27.42 Million | -1.01% |
| Share Repurchases | $374.35 Million | -13.81% |
| Other Comprehensive Income | $753.23 Million | +27.79% |
| Other Changes | $-1.40 Billion | -51.57% |
| Total Change | $- | 1.17% |
Book Value vs Market Value Analysis
This analysis compares Integrated Diagnostics Holdings plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $13.57 | $0.32 | x |
| 2013-12-31 | $3.18 | $0.32 | x |
| 2014-12-31 | $3.02 | $0.32 | x |
| 2015-12-31 | $3.16 | $0.32 | x |
| 2016-12-31 | $3.73 | $0.32 | x |
| 2017-12-31 | $3.74 | $0.32 | x |
| 2018-12-31 | $3.78 | $0.32 | x |
| 2019-12-31 | $3.69 | $0.32 | x |
| 2020-12-31 | $3.78 | $0.32 | x |
| 2021-12-31 | $4.30 | $0.32 | x |
| 2022-12-31 | $3.59 | $0.32 | x |
| 2023-12-31 | $4.46 | $0.32 | x |
| 2024-12-31 | $4.57 | $0.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Integrated Diagnostics Holdings plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 39.76%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.84%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 2.63x
- Recent ROE (39.76%) is above the historical average (19.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 1.21% | 3.84% | 0.26x | 1.20x | $-178.87 Million |
| 2013 | 3.25% | 9.25% | 0.29x | 1.20x | $-128.79 Million |
| 2014 | 7.32% | 15.43% | 0.38x | 1.23x | $-48.50 Million |
| 2015 | 7.64% | 14.28% | 0.41x | 1.31x | $-44.69 Million |
| 2016 | 11.64% | 22.24% | 0.38x | 1.36x | $36.67 Million |
| 2017 | 16.66% | 24.70% | 0.49x | 1.39x | $149.46 Million |
| 2018 | 22.12% | 26.13% | 0.56x | 1.51x | $275.09 Million |
| 2019 | 23.06% | 22.95% | 0.59x | 1.70x | $289.38 Million |
| 2020 | 26.17% | 22.36% | 0.64x | 1.84x | $367.02 Million |
| 2021 | 54.69% | 27.04% | 0.84x | 2.41x | $1.15 Billion |
| 2022 | 25.12% | 15.01% | 0.68x | 2.46x | $325.70 Million |
| 2023 | 19.05% | 12.38% | 0.71x | 2.15x | $242.41 Million |
| 2024 | 39.76% | 18.84% | 0.80x | 2.63x | $806.42 Million |
Industry Comparison
This section compares Integrated Diagnostics Holdings plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Integrated Diagnostics Holdings plc (IDGXF) | $3.83 Billion | 1.21% | 0.96x | $74.41 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |